Bavarian Nordic: We can adapt our vaccine if necessary

If it needs to, Bavarian Nordic will be able to keep pace with Moderna and Pfizer/Biontech and change its Covid-19 vaccine so it works against the Omicron variant.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by catherine brett

It is not yet known whether the current Covid-19 vaccines are effective against the Omicron variant of the coronavirus, or whether they will need to be adapted, says Rolf Sass Sørensen, vice president of investor relations at Bavarian Nordic, to MarketWire. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading